Real-World Study of Iruplinalkib in the Treatment of ALK-Positive Non-Small Cell Lung Cancer

Last updated: August 8, 2023
Sponsor: Jinming Yu
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

Iruplinalkib

Clinical Study ID

NCT05991895
IRU-RWS-001
  • Ages > 18
  • All Genders

Study Summary

This study is a national multicenter real-world investigation aimed at evaluating the real-world effectiveness and safety of Iruplinalkib in the treatment of ALK-positive NSCLC in China.

The study aims to enroll ALK-positive NSCLC patients who have undergone treatment with Iruplinalkib prior to enrollment. Demographic information, medical history, Iruplinalkib-containing treatment regimens, clinical outcomes, adverse events, and related data will be collected for all enrolled patients.

As this study is a real-world investigation, treatment procedures, visit schedules, and examinations will be based on the routine clinical practice of physicians. The primary sources of data for this study will mainly consist of patients' routine medical records or healthcare documentation.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients willingly contribute their clinical data for this study
  • Patients with ALK-positive non-small cell lung cancer
  • Age ≥ 18 years
  • Patients who have undergone treatment with Iruplinalkib.

Exclusion

Exclusion Criteria:

  • Known pregnant or lactating females
  • Patients with interstitial lung diseases, drug-related pneumonitis, or radiationpneumonitis require ongoing medical intervention.

Study Design

Total Participants: 5000
Treatment Group(s): 1
Primary Treatment: Iruplinalkib
Phase:
Study Start date:
July 24, 2023
Estimated Completion Date:
July 31, 2026

Connect with a study center

  • Shandong Cancer Hospital and Institute

    Jinan, Shandong
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.